Key Points
- ANI Pharmaceuticals CEO Nikhil Lalwani sold 5,400 shares for $388,206 at an average price of $71.89 under a pre-arranged Rule 10b5-1 trading plan, reducing his stake by 1.59% to 333,689 shares.
- ANI reported quarterly adjusted earnings of $2.21 per share and revenue of $266.04 million, surpassing analyst estimates; revenue increased 25.8% year over year.
- Shares recently traded at $72.29, while analysts maintain an average “Hold” rating and a $99.60 price target. Institutional investors own approximately 76.05% of the company.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) CEO Nikhil Lalwani sold 5,400 shares of the firm's stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $71.89, for a total value of $388,206.00. Following the completion of the transaction, the chief executive officer owned 333,689 shares of the company's stock, valued at $23,988,902.21. This trade represents a 1.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Nikhil Lalwani also recently made the following trade(s):
- On Tuesday, September 15th, Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $71.00, for a total value of $383,400.00.
- On Tuesday, August 25th, Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $74.30, for a total value of $401,220.00.
ANI Pharmaceuticals Stock Performance
ANI Pharmaceuticals stock traded up $0.01 during trading hours on Friday, hitting $72.29. 333,921 shares of the stock traded hands, compared to its average volume of 412,460. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. The firm's 50 day moving average price is $73.59 and its 200-day moving average price is $77.97. The stock has a market capitalization of $1.66 billion, a price-to-earnings ratio of 15.58, a P/E/G ratio of 2.33 and a beta of 0.50. ANI Pharmaceuticals, Inc. has a 1 year low of $69.58 and a 1 year high of $97.00.
ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating analysts' consensus estimates of $2.04 by $0.17. The business had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%. The company's revenue was up 25.8% on a year-over-year basis. During the same period in the prior year, the company earned $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts expect that ANI Pharmaceuticals, Inc. will post 7.76 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on the company. Canaccord Genuity Group dropped their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating on the stock in a research report on Monday, August 10th. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 9th. They set an "outperform" rating and a $104.00 price target for the company. Oppenheimer started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They set a "market perform" rating and a $85.00 price objective for the company. Weiss Ratings cut shares of ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Tuesday, August 11th. Finally, Guggenheim dropped their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating on the stock in a report on Monday, August 10th. Three analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, ANI Pharmaceuticals presently has an average rating of "Hold" and an average price target of $99.60.
Check Out Our Latest Report on ANIP
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of ANIP. Arrowstreet Capital Limited Partnership lifted its holdings in ANI Pharmaceuticals by 19.3% in the first quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company's stock valued at $43,399,000 after acquiring an additional 91,153 shares during the period. Dimensional Fund Advisors LP boosted its position in ANI Pharmaceuticals by 8.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company's stock worth $40,843,000 after purchasing an additional 43,523 shares in the last quarter. Ranger Investment Management L.P. acquired a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth approximately $28,406,000. Deutsche Bank AG acquired a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth approximately $26,775,000. Finally, William Blair Investment Management LLC acquired a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth approximately $21,372,000. 76.05% of the stock is owned by institutional investors and hedge funds.
About ANI Pharmaceuticals
(
Get Free Report)
ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes branded and generic prescription medicines. The company focuses on products with complex formulations, difficult-to-manufacture dosage forms and limited competition, serving therapeutic areas that include rare diseases, ophthalmology, endocrinology, central nervous system conditions and other specialty markets.
ANI's portfolio includes Cortrophin Gel (repository corticotropin injection), a specialty therapy used for certain inflammatory and autoimmune conditions, as well as a range of established brand and generic products.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
